Dec 14, 2020   SOURCE: PR NewsWire

Global Acute Respiratory Distress Syndrome (ARDS) Market Outlook: COVID-19 Associated with ARDS and Emerging Drugs

DUBLIN, Dec. 14, 2020 /PRNewswire/ -- The "Acute Respiratory Distress Syndrome (ARDS) Market Insight, Epidemiology and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering.

https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

This report delivers an in-depth understanding of the Acute Respiratory Distress Syndrome (ARDS), historical and forecasted epidemiology as well as the Acute Respiratory Distress Syndrome (ARDS) market trends in the United States, EU5 (Germany, France, Italy, and United Kingdom) and Japan.

The Acute Respiratory Distress Syndrome (ARDS) market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM Acute Respiratory Distress Syndrome (ARDS) market size from 2017 to 2030. The report also covers current Acute Respiratory Distress Syndrome (ARDS) treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

Scope of the Report

    --  The report covers the descriptive overview of Acute Respiratory Distress
        Syndrome (ARDS), explaining its causes, signs and symptoms, pathogenesis
        and currently available therapies.
    --  Comprehensive insight has been provided into the Acute Respiratory
        Distress Syndrome (ARDS) epidemiology and treatment.
    --  Additionally, an all-inclusive account of both the current and emerging
        therapies for Acute Respiratory Distress Syndrome (ARDS) are provided,
        along with the assessment of new therapies, which will have an impact on
        the current treatment landscape.
    --  A detailed review of Acute Respiratory Distress Syndrome (ARDS) market;
        historical and forecasted is included in the report, covering the 7MM
        drug outreach.
    --  The report provides an edge while developing business strategies, by
        understanding trends shaping and driving the 7MM Acute Respiratory
        Distress Syndrome (ARDS) market.

Report Highlights

    --  Total Incident Population of Acute Respiratory Distress Syndrome (ARDS)
        in the 7MM is anticipated to rise in the forecasted period (2017-2030).
    --  The market for ARDS in the 7MM is projected to rise during the study
        period (2017-2030).
    --  Dynamic research and developmental activity with 60+ companies in the
        pipeline at different stages.
    --  In the coming years, Acute Respiratory Distress Syndrome (ARDS) market
        is set to change due to the rising awareness of the disease, and
        incremental healthcare spending across the world; which would expand the
        size of the market to enable the drug manufacturers to penetrate more
        into the market.
    --  The companies and academics are working to assess challenges and seek
        opportunities that could influence Acute Respiratory Distress Syndrome
        (ARDS) R&D. The therapies under development are focused on novel
        approaches to treat/improve the disease condition.
    --  Major players are involved in developing therapies for Acute Respiratory
        Distress Syndrome (ARDS). Launch of emerging therapies will
        significantly impact the Acute Respiratory Distress Syndrome (ARDS)
        market.
    --  The in-depth analysis of the pipeline assets across different stages of
        development (phase III and phase II), different emerging trends and
        comparative analysis of pipeline products with detailed clinical
        profiles, key cross-competition, launch date along with product
        development activities will support the clients in the decision-making
        process regarding their therapeutic portfolio by identifying the overall
        scenario of the research and development activities

Key Topics Covered:

1 Key Insights

2 Executive Summary

3 Acute Respiratory Distress Syndrome (ARDS): Market Overview at a Glance

4 Acute Respiratory Distress Syndrome (ARDS): Disease Background and Overview

5 Case Reports

6 Epidemiology and Patient Population

7 7MM Epidemiology Analysis

8 United States Epidemiology

9 EU5 Epidemiology

10 Japan Epidemiology

11 Treatment Algorithm, Current Treatment, and Medical Practices

12 Proposed Guidelines for ARDS

13 Unmet Needs

14 Off-Label Therapies for ARDS

15 Emerging Therapies

16 Unknown Status

17 COVID-19 associated with ARDS: Emerging Drugs

18 Discontinued Products

19 Acute Respiratory Distress Syndrome (ARDS): 7MM Market Analysis

20 Attribute Analysis

21 Key Emerging Therapies: Market Forecast Assumptions

22 United States: Market Outlook

23 EU-5 Countries: Market Outlook

24 Japan Market Outlook

25 Access and Reimbursement

26 Market Drivers

27 Market Barriers

28 SWOT Analysis

Companies Mentioned 

    --  Ache Laboratorios Farmaceuticos
    --  Alexion Pharmaceuticals
    --  Algernon Pharmaceuticals
    --  Ampio Pharmaceuticals Inc.
    --  Apeiron Biologics
    --  Apeptico Forschung und Entwicklung GmbH
    --  Aqualung Therapeutics Corp.
    --  Athersys
    --  aTyr Pharma
    --  Bioaegis Therapeutics Inc.
    --  Biohaven Pharmaceutical Holding Co. Ltd.
    --  Biomarck Pharmaceuticals
    --  Bioxytran Inc.
    --  Caladrius Biosciences Inc.
    --  Cellenkos Inc
    --  Celularity Inc.; Sorrento Therapeutics Inc.; Lung Biotechnology PBC, a
        subsidiary of United Therapeutics Corp.
    --  Cerecor Inc.
    --  Chimerix
    --  Cyclacel Pharmaceuticals
    --  CytoDyn
    --  Diffusion Pharmaceuticals Inc.; University of Virginia
    --  Direct Biologics
    --  Eli Lilly and Company
    --  Faron Pharmaceuticals
    --  GEn1E Lifesciences
    --  GlaxoSmithKline
    --  Histocell, S.L.
    --  Hospital to Academy of Military Medical Sciences/Ivy Institute of Stem
        Cells Co. Ltd
    --  Humanigen, Inc.
    --  Iltoo Pharma
    --  Implicit Bioscience
    --  Kinevant Sciences GmbH/Roivant Sciences
    --  Kiniksa
    --  Kiniksa Pharmaceuticals
    --  Laboratoire francais de Fractionnement et de Biotechnologies
    --  Lamellar Biomedical Ltd.
    --  Lattice Biologics Ltd.
    --  Leading Biosciences Inc.
    --  Mallinckrodt /Novoteris LLC
    --  Mannkind Corp.; Immix Biopharma Inc.
    --  Medicinova Inc.
    --  Merck/Eli Lilly
    --  Meridigen Biotech
    --  Mesoblast Limited
    --  Mylan Laboratories
    --  Navigen pharmaceuticals
    --  NeuroRx/Relief Therapeutics
    --  Noveome Biotherapeutics
    --  Noxopharm Co.
    --  Pharmazz
    --  PhaseBio Pharmaceuticals
    --  Pluristem Therapeutics
    --  Predictive Biotech, of Salt Lake City, a subsidiary of Predictive
        Technology Group
    --  Quark Pharmaceuticals
    --  Roche Pharma AG
    --  Sage Therapeutics
    --  Theravance Biopharma,
    --  Tiziana
    --  Vanda Pharmaceuticals Inc.; the University of Illinois at Chicago
    --  Veru
    --  Windtree Therapeutics
    --  XORTX Therapeutics
    --  ZyVersa Therapeutics

For more information about this report visit https://www.researchandmarkets.com/r/cwxz59

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/global-acute-respiratory-distress-syndrome-ards-market-outlook-covid-19-associated-with-ards-and-emerging-drugs-301192030.html

SOURCE Research and Markets